Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Bioquark Inc. and Ectocrine Technologies LLC to Collaborate on Mosquito-Derived Health Product Development

The common mosquito, while being responsible for up to a million human deaths each year, may paradoxically also hold biochemical secrets to cure diseases that effect hundreds of millions of people around the globe. This collaboration, between Bioquark Inc. and Ectocrine Technologies LLC, is the first of its kind to explore the possibilities for the benefit of humanity.


News provided by

Bioquark Inc.

Dec 21, 2018, 16:00 ET

Share this article

Share toX

Share this article

Share toX

Youtube
Youtube

PHILADELPHIA, Dec. 21, 2018 /PRNewswire-PRWeb/ -- Bioquark, Inc., (http://www.bioquark.com) an innovative life sciences company focused biotherapeutic development for human regeneration and disease reversion, and Ectocrine Technologies LLC, a biotech company dedicated to studying the positive human physiological effects of salivary secretions of hematophagous arthropods, such as mosquitos, of have announced a collaboration to focus on developing novel bio-products for human health and wellness.

"We are very excited about this collaboration with Ectocrine Technologies," said Ira S. Pastor, CEO, Bioquark Inc. "The synergy of our approaches in studying evolutionarily perfected arrays of metabolites from the natural world, can lead to the development of novel therapeutics for a range of chronic diseases responsible for human degeneration and suffering. And nature's ectocrine systems (the "Ectocrinome") represents a completely un-tapped reservoir."

"The synergy of our approaches in studying evolutionarily perfected arrays of metabolites from the natural world, can lead to the development of novel therapeutics for a range of chronic diseases responsible for human degeneration and suffering." - Ira S. Pastor, CEO, Bioquark Inc.

Post this

Nature's ectocrine systems (or "Ectocrinome", in similar model to the Microbiome), form an interlaced network across species, providing a range of beneficial bio-active effects. The saliva of mosquitos, as example, has been shown to contain novel neuro-peptides, anti-inflammatory molecules, anti-coagulants, pain killers, as well as a range of vasodilatory and immune-modulatory molecules. However, most of this knowledge has been completely obscured due to the extensive popular press focus on the mosquito being no more than a disease carrying pest.

Mosquito eradication programs, while offering a solution to the million deaths each year from mosquito born disease, ignore the critical immunopathological role that these creatures have played over hundreds of millions of years as they propagated their beneficial biochemical signals in invertebrates, fish, amphibians, reptiles, birds, mammals, and humans. While hygiene represents one of the most successful health / life extending interventions in history, many epidemiological studies show that, paradoxically, it may render humans at risk for the development of a range of chronic non-communicable diseases (NCDs), such as inflammatory bowel disease, multiple sclerosis, type I diabetes, asthma, and allergies. Furthermore, these pathological process might play a broad role in the pathogenesis of other NCDs associated with chronic inflammation such as atherosclerosis, type 2 diabetes, cancer, and neurodegenerative disorders.

"We look forward to working closely with Bioquark Inc. on this exciting initiative," said Dr. J. Santiago Mejia MD, CSO of Ectocrine Technologies LLC. "The epidemiological evidence of low incidences of auto-immune diseases, inflammatory disorders, allergies, developmental diseases and certain cancers, in regions of high endemicity for arthropod-borne diseases, may interestingly point us towards previously ignored answers to combat these major causes of human degeneration and disease."

"We are not advocating for the suspension of the vector control programs used to eradicate malaria and other arthropod-borne diseases. Our concern is that these methods fail to discriminate infected from non-infected mosquitos, and as a result, residents of intervened areas are deprived of the potential health benefits derived from exposure to the salivary molecules delivered through the bite of healthy mosquitos," said Mejia.

About Bioquark, Inc.

Bioquark Inc. (http://www.bioquark.com) is an innovative life sciences company focused on the development of novel bio-products for human regeneration, disease reversion and rejuvenation, in relation to aging and age related pathologies.

About Ectocrine Technologies

Ectocrine Technologies LLC is a biotech company dedicated to studying the positive human physiological effects of salivary secretions of hematophagous arthropods, such as mosquitos, as an essential source of molecules for human well-being and development.

SOURCE Bioquark Inc.

Related Links

http://www.bioquark.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.